STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: On account of the effects of icaritin in disturbing the signaling of JAK2/STAT3/AKT on CML cells, we try to determine whether icaritin is able to target the IL-6/JAK2/STAT3 driven-signalings on MM cells.